US FDA targets December for Alexza drug decision
This article was originally published in Scrip
Executive Summary
The US FDA accepted Alexza Pharmaceuticals' resubmitted application for Adasuve (Staccato loxapine), an inhaled medicine under investigation as an acute treatment for agitation associated with schizophrenia or bipolar I disorder in adults, setting 21 December as the new Prescription Drug User Fee Act action date, declaring it a Class 2 response.